AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23957902 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard intention condition
Number of subjects: 7000
Study 23957902 — intervention group
Group type: EXPERIMENTAL
Intervention: Interrogative intention condition
Number of subjects: 7000
Study 23957902 — intervention group
Group type: EXPERIMENTAL
Intervention: Regret plus intention condition
Number of subjects: 7000
Study 23957902 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 7000
Study 22669134 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal and pelvic floor muscle retraining (including diaphragmatic breathing exercises)
Number of subjects: 43
Study 18495456 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary treatment with varying total choline (344-486 mg/day), betaine (122-349 mg/day) and/or folate (400-800 microg dietary folate equivalents/day) for 12 weeks
Number of subjects: 45
Study 18495456 — intervention group
Group type: EXPERIMENTAL
Intervention: MTHFR C677T genotype
Number of subjects: 45
Study 20943715 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual locomotor imagery training
Number of subjects: 15
Study 20943715 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic locomotor imagery training with auditory step rhythm
Number of subjects: 15
Study 20943715 — intervention group
Group type: EXPERIMENTAL
Intervention: Kinesthetic locomotor imagery training
Number of subjects: 15
Study 15921475 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation strategy (2 sessions with education, group discussion, role playing, feedback, and reminders)
Number of subjects: 500
Study 15921475 — intervention group
Group type: COMPARATOR
Intervention: Standard passive method of dissemination (guidelines by mail)
Number of subjects: 500
Study 15921475 — intervention group
Group type: EXPERIMENTAL
Intervention: Active implementation strategy
Number of subjects: 500
Study 15921475 — intervention group
Group type: COMPARATOR
Intervention: Standard passive method of dissemination
Number of subjects: 500
Study 11883349 — intervention group
Group type: EXPERIMENTAL
Intervention: 10‐mg PGE2 vaginal insert
Number of subjects: 200
Study 11883349 — intervention group
Group type: COMPARATOR
Intervention: 3‐mg PGE2 tablets (administered twice at six‐hour intervals)
Number of subjects: 200
Study 11883349 — intervention group
Group type: COMPARATOR
Intervention: 3‐mg PGE2 tablets
Number of subjects: 200
Study 10084465 — intervention group
Group type: EXPERIMENTAL
Intervention: Salbutamol (1,200 microg)
Number of subjects: 17
Study 10084465 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study 7737632 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic acid (URSO)
Number of subjects: 69
Study 7737632 — intervention group
Group type: EXPERIMENTAL
Intervention: Colchicine
Number of subjects: 69
Study 7737632 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 2115444 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin (10 mg(24 h)‐1)
Number of subjects: 16
Study 2115444 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nitroglycerin (mean dose: 40 +/‐ 9 micrograms min‐1)
Number of subjects: 16
Study 7355391 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetadine (three preoperative doses)
Number of subjects: 84
Study 7355391 — intervention group
Group type: COMPARATOR
Intervention: Glycopyrrolate (0.005 mg/kg)
Number of subjects: 84
Study 7355391 — intervention group
Group type: COMPARATOR
Intervention: Atropine (0.01 mg/kg)
Number of subjects: 84
Study 31711605 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 2 mg
Number of subjects: 18
Study 31711605 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 4 mg
Number of subjects: 18
Study 31711605 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. dexamethasone 8 mg
Number of subjects: 18
Study 31711605 — intervention group
Group type: COMPARATOR
Intervention: saline
Number of subjects: 18
Study 30567598 — intervention group
Group type: EXPERIMENTAL
Intervention: Active music-instruction intervention
Number of subjects: 68
Study 26921136 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal progesterone, 200 mg daily from 22-24 to 34 weeks of gestation
Number of subjects: 1228
Study 26921136 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1228
Study 24052092 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (10-week intervention)
Number of subjects: 76
Study 24052092 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 76
Study 22705425 — intervention group
Group type: EXPERIMENTAL
Intervention: INE+MNP
Number of subjects: 215
Study 22705425 — intervention group
Group type: EXPERIMENTAL
Intervention: INE
Number of subjects: 215
Study 22705425 — intervention group
Group type: EXPERIMENTAL
Intervention: NNE+MNP
Number of subjects: 215
Study 22705425 — intervention group
Group type: EXPERIMENTAL
Intervention: NNE
Number of subjects: 215
Study 20209088 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D (≥800 IU orally daily)
Number of subjects: 12875
Study 20209088 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip protectors
Number of subjects: 12875
Study 20209088 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoride
Number of subjects: 12875
Study 20209088 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunlight exposure
Number of subjects: 12875
Study 20209088 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise or multimodal interventions
Number of subjects: 12875
Study 20209088 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate
Number of subjects: 12875
Study 20209088 — intervention group
Group type: EXPERIMENTAL
Intervention: Staff education and risk assessment strategy
Number of subjects: 12875
Study 18520275 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified forearm minidose intravenous regional anesthesia (IVRA)
Number of subjects: 62
Study 18520275 — intervention group
Group type: COMPARATOR
Intervention: Conventional minidose intravenous regional anesthesia (IVRA)
Number of subjects: 62
Study 15925082 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20mg on demand (maximum one dose per day before sexual activity)
Number of subjects: 4262
Study 15925082 — intervention group
Group type: COMPARATOR
Intervention: Tadalafil 20mg 3 times/week
Number of subjects: 4262
Study 12182445 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist
Number of subjects: 0
Study 12182445 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist
Number of subjects: 0
Study 12182445 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin
Number of subjects: 0
Study 10496513 — intervention group
Group type: EXPERIMENTAL
Intervention: Transference interpretations
Number of subjects: 40
Study 7579093 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma clearance of iohexol (single iv dose)
Number of subjects: 41
Study 7579093 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma clearance of iohexol
Number of subjects: 41
Study 7579093 — intervention group
Group type: EXPERIMENTAL
Intervention: GFR determined with iohexol
Number of subjects: 41
Study 1782726 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral cyclosporin A
Number of subjects: 12
Study 1782726 — intervention group
Group type: COMPARATOR
Intervention: Vehicle placebo
Number of subjects: 12
Study 7006285 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg of methylprednisolone
Number of subjects: 26
Study 7006285 — intervention group
Group type: COMPARATOR
Intervention: Control (no methylprednisolone)
Number of subjects: 26
Study 31166984 — intervention group
Group type: EXPERIMENTAL
Intervention: Male Partner Involvement (Phase 2)
Number of subjects: 1424
Study 31166984 — intervention group
Group type: COMPARATOR
Intervention: No Male Partner Involvement (Phase 1)
Number of subjects: 1424
Study 30025692 — intervention group
Group type: EXPERIMENTAL
Intervention: Catheter ablation with endpoint of noninducibility of VT ≥300 ms after ablation
Number of subjects: 129
Study 30025692 — intervention group
Group type: COMPARATOR
Intervention: Inducible VT or inducibility testing not performed
Number of subjects: 129
Study 26493396 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous caudal epidural bupivacaine 0.125 % with fentanyl, IV fentanyl, and paracetamol
Number of subjects: 60
Study 26493396 — intervention group
Group type: COMPARATOR
Intervention: IV fentanyl and paracetamol
Number of subjects: 60
Study 24574190 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD + virgin olive oil (VOO)
Number of subjects: 930
Study 24574190 — intervention group
Group type: EXPERIMENTAL
Intervention: TMD + nuts
Number of subjects: 930
Study 24574190 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (control)
Number of subjects: 930
Study 23338262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortify
Number of subjects: 40
Study 23338262 — intervention group
Group type: EXPERIMENTAL
Intervention: Fortify Plus
Number of subjects: 40
Study 23338262 — intervention group
Group type: EXPERIMENTAL
Intervention: Biscover LV
Number of subjects: 40
Study 23338262 — intervention group
Group type: COMPARATOR
Intervention: Control group (no surface treatment)
Number of subjects: 40
Study 20061693 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraluminal vancomycin (500 mg infusion via both lumens of the Permcath and antibiotic lock of 1.5 mL every 48 hours) and intravenous ceftriaxone (1 g every 12 hours for 7 days) followed by oral antibiotics for three weeks
Number of subjects: 67
Study 20061693 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vancomycin (500 mg) and daily intravenous amikacin (100-150 mg)
Number of subjects: 67
Study 18834241 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy before 21 weeks' gestation
Number of subjects: 0
Study 18834241 — intervention group
Group type: COMPARATOR
Intervention: Control group (periodontal treatment after delivery)
Number of subjects: 0
Study 18834241 — intervention group
Group type: EXPERIMENTAL
Intervention: Periodontal therapy
Number of subjects: 0
Study 16095436 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment telephone call by a nurse quitline counselor
Number of subjects: 625
Study 16095436 — intervention group
Group type: EXPERIMENTAL
Intervention: Recruitment postcard
Number of subjects: 625
Study 16095436 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 625
Study 11755281 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 206
Study 11755281 — intervention group
Group type: COMPARATOR
Intervention: Conventional stenting
Number of subjects: 206
Study 9400462 — intervention group
Group type: EXPERIMENTAL
Intervention: 60 Gy external radiotherapy with 18 MV photon beams between 12 and 16 weeks postoperatively
Number of subjects: 100
Study 9400462 — intervention group
Group type: COMPARATOR
Intervention: Surveillance (no radiotherapy)
Number of subjects: 100
Study 7521895 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) +/‐ azathioprine (n = 10)
Number of subjects: 20
Study 7521895 — intervention group
Group type: EXPERIMENTAL
Intervention: FK 506 (n = 10)
Number of subjects: 20
Study 7521895 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects (n = 10)
Number of subjects: 20
Study 2670915 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine (15 mg p.o. twice daily)
Number of subjects: 18
Study 2670915 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 2670915 — intervention group
Group type: EXPERIMENTAL
Intervention: d-fenfluramine
Number of subjects: 18
Study 984522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bisolvon intravenously
Number of subjects: 40
Study 31828479 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged phase change material (PCM) cooling
Number of subjects: 26
Study 31828479 — intervention group
Group type: COMPARATOR
Intervention: Melted packs (control)
Number of subjects: 26
Study 31808923 — intervention group
Group type: EXPERIMENTAL
Intervention: Glioma Index constructed using 3 microRNAs (miR-4763-3p, miR-1915-3p, and miR-3679-5p)
Number of subjects: 580
Study 31808923 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-Tumor Index constructed using 48 microRNAs
Number of subjects: 580
Study 27325179 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered outcomes research involving community engagement over 18 months.
Number of subjects: 31
Study 27325179 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based participatory principles in research design.
Number of subjects: 31
Study 25825855 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐week multidisciplinary clinical hunger provocation program
Number of subjects: 22
Study 25825855 — intervention group
Group type: COMPARATOR
Intervention: 4‐week outpatient treatment by the same multidisciplinary team
Number of subjects: 22
Study 23006632 — intervention group
Group type: COMPARATOR
Intervention: Cholecystokinin (CCK) during ramp distension
Number of subjects: 44
Study 23006632 — intervention group
Group type: COMPARATOR
Intervention: Cholecystokinin (CCK) during intermittent distension
Number of subjects: 44
Study 23006632 — intervention group
Group type: COMPARATOR
Intervention: Placebo during ramp distension
Number of subjects: 44
Study 23006632 — intervention group
Group type: COMPARATOR
Intervention: Placebo during intermittent distension
Number of subjects: 44
Study 21764118 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (150 mg per day)
Number of subjects: 326
Study 21764118 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirtazapine (45 mg)
Number of subjects: 326
Study 21764118 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 326
Study 19517423 — intervention group
Group type: EXPERIMENTAL
Intervention: 75 mg venlafaxine tablets
Number of subjects: 32
Study 17082465 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded motor imagery (2 weeks each of limb laterality recognition, imagined movements, and mirror movements)
Number of subjects: 51
Study 17082465 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy and ongoing medical care (Control)
Number of subjects: 51
Study 15022300 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy Conservation and Activity Management (ECAM) intervention
Number of subjects: 396
Study 15022300 — intervention group
Group type: COMPARATOR
Intervention: Control intervention focused on nutrition
Number of subjects: 396
Study 11717207 — intervention group
Group type: EXPERIMENTAL
Intervention: Unidirectional rotation (UNI)
Number of subjects: 60
Study 11717207 — intervention group
Group type: EXPERIMENTAL
Intervention: Bidirectional needle rotation (BI)
Number of subjects: 60
Study 11717207 — intervention group
Group type: COMPARATOR
Intervention: No rotation (NO)
Number of subjects: 60
Study 11717207 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture points
Number of subjects: 60
Study 11717207 — intervention group
Group type: COMPARATOR
Intervention: Control points
Number of subjects: 60
Study 9728903 — intervention group
Group type: EXPERIMENTAL
Intervention: Tianeptine
Number of subjects: 69
Study 9728903 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 7991719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3,4‐dihydroxyphenylacetic acid (DOPAC)
Number of subjects: 20
Study 7991719 — intervention group
Group type: EXPERIMENTAL
Intervention: 3‐hydroxykynurenine
Number of subjects: 20
Study 7991719 — intervention group
Group type: EXPERIMENTAL
Intervention: metanephrine
Number of subjects: 20
Study 7991719 — intervention group
Group type: COMPARATOR
Intervention: standard dose of neuroleptic
Number of subjects: 20
Study 2604291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined formulation of isoniazid (125 mg), rifampin (100 mg), and pyrazinamide (375 mg)
Number of subjects: 627
Study 2604291 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations of isoniazid, rifampin, and pyrazinamide
Number of subjects: 627
Study 2604291 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined formulation
Number of subjects: 627
Study 2604291 — intervention group
Group type: COMPARATOR
Intervention: Separate formulations
Number of subjects: 627
Study 31037783 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental exposure to a prototypical alcohol brand
Number of subjects: 109
Study 31037783 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental exposure to a non-prototypical alcohol brand
Number of subjects: 109
Study 31037783 — intervention group
Group type: EXPERIMENTAL
Intervention: Incidental exposure to a brand unrelated to alcohol
Number of subjects: 109
Study 31037783 — intervention group
Group type: COMPARATOR
Intervention: Cognitively depleting task
Number of subjects: 109
Study 31037783 — intervention group
Group type: COMPARATOR
Intervention: Control task
Number of subjects: 109
Study 28765194 — intervention group
Group type: EXPERIMENTAL
Intervention: Green Tea Extract (GTE)
Number of subjects: 1021
Study 28765194 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1021
Study 26391052 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulator-integrated tutoring
Number of subjects: 22
Study 26391052 — intervention group
Group type: COMPARATOR
Intervention: Self-directed practice without tutoring
Number of subjects: 22
Study 23271193 — intervention group
Group type: COMPARATOR
Intervention: Drug Effects Questionnaire (DEQ) for amphetamine
Number of subjects: 0
Study 23271193 — intervention group
Group type: COMPARATOR
Intervention: Drug Effects Questionnaire (DEQ) for nicotine
Number of subjects: 0
Study 23271193 — intervention group
Group type: COMPARATOR
Intervention: Drug Effects Questionnaire (DEQ) for alcohol
Number of subjects: 0
Study 21699471 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical total disc replacement (CTDR) using Kineflex|C
Number of subjects: 269
Study 21699471 — intervention group
Group type: COMPARATOR
Intervention: Anterior cervical discectomy and fusion (ACDF)
Number of subjects: 269
Study 18503496 — intervention group
Group type: EXPERIMENTAL
Intervention: Cow's milk-based infant formula
Number of subjects: 94
Study 18503496 — intervention group
Group type: COMPARATOR
Intervention: Control group (autoantibody negative subjects)
Number of subjects: 94
Study 16835255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate (MgSO4) 10 ml (50 mg/ml)
Number of subjects: 60
Study 16835255 — intervention group
Group type: COMPARATOR
Intervention: Normal saline 10 ml (Control Group)
Number of subjects: 60
Study 16835255 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular magnesium sulphate (MgSO4)
Number of subjects: 60
Study 16835255 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (Control Group)
Number of subjects: 60
Study 11808835 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking cessation
Number of subjects: 51
Study 11808835 — intervention group
Group type: COMPARATOR
Intervention: Smoking reduction (4-8 cigarettes daily)
Number of subjects: 51
Study 11808835 — intervention group
Group type: COMPARATOR
Intervention: Continued smoking
Number of subjects: 51
Study 10417457 — intervention group
Group type: COMPARATOR
Intervention: Noncricoid pressure
Number of subjects: 50
Study 10417457 — intervention group
Group type: EXPERIMENTAL
Intervention: Cricoid pressure
Number of subjects: 50
Study 8775880 — intervention group
Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy
Number of subjects: 0
Study 8775880 — intervention group
Group type: COMPARATOR
Intervention: Standard medical therapy with aspirin
Number of subjects: 0
Study 8775880 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 0
Study 8775880 — intervention group
Group type: COMPARATOR
Intervention: Novel antiplatelet and antithrombotic agents
Number of subjects: 0
Study 2342740 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth prevention program consisting of risk scoring, intensive weekly observation including cervical examinations, and detailed education about preterm labor signs and symptoms.
Number of subjects: 1000
Study 2342740 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm birth prevention program (treatment group).
Number of subjects: 1000
Study 2342740 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified).
Number of subjects: 1000
Study 7449720 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of Quinupramine
Number of subjects: 32
Study 7449720 — intervention group
Group type: COMPARATOR
Intervention: Oral administration of Quinupramine
Number of subjects: 32
Study 6832466 — intervention group
Group type: EXPERIMENTAL
Intervention: Indobufen (200 mg single oral dose)
Number of subjects: 20
Study 6832466 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 30935809 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound (US), continuous ultrasound, intensity 1.5 w/cm2, frequency 1 MHz, duration 10 minutes
Number of subjects: 32
Study 30935809 — intervention group
Group type: COMPARATOR
Intervention: Radial extracorporeal shock wave therapy (rESWT), 0.340 mJ/mm2, 2000 shots
Number of subjects: 32
Study 29160925 — intervention group
Group type: EXPERIMENTAL
Intervention: Swaddled bathing (SB)
Number of subjects: 80
Study 29160925 — intervention group
Group type: COMPARATOR
Intervention: Traditional tub bathing (TTB)
Number of subjects: 80
Study 26687020 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-wave diathermy and interferential currents (ITH)
Number of subjects: 67
Study 26687020 — intervention group
Group type: COMPARATOR
Intervention: Long-wave diathermy at low power (LDL)
Number of subjects: 67
Study 25377370 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone (hypnotic doses)
Number of subjects: 50
Study 25377370 — intervention group
Group type: COMPARATOR
Intervention: Zopiclone (hypnotic agent)
Number of subjects: 50
Study 22971488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Number of subjects: 198
Study 22971488 — intervention group
Group type: COMPARATOR
Intervention: Midazolam
Number of subjects: 198
Study 21169106 — intervention group
Group type: EXPERIMENTAL
Intervention: Capsaicin
Number of subjects: 48
Study 21169106 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 48
Study 18946743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 2 g BID, methimazole, and propranolol
Number of subjects: 45
Study 18946743 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine 1 g BID, methimazole, and propranolol
Number of subjects: 45
Study 18946743 — intervention group
Group type: COMPARATOR
Intervention: Placebo powder, methimazole, and propranolol
Number of subjects: 45